The KEYNOTE-826 trial demonstrated that the addition of pembrolizumab to cisplatin/paclitaxel chemotherapy, with or without bevacizumab, in patients with PD-L1-positive recurrent cervical cancer significantly improved outcomes. This evidence concerns the gene CD274 and cervical carcinoma.